BioMarin Pharmaceutical Future Growth

Future criteria checks 4/6

BioMarin Pharmaceutical is forecast to grow earnings and revenue by 29.8% and 10.8% per annum respectively. EPS is expected to grow by 28.7% per annum. Return on equity is forecast to be 12.7% in 3 years.

Key information

29.8%

Earnings growth rate

28.7%

EPS growth rate

Biotechs earnings growth	25.0%
Revenue growth rate	10.8%
Future return on equity	12.7%
Analyst coverage	Good
Last updated	23 May 2024

Recent future growth updates

Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Apr 26

Recent updates

BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain

May 15

Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Apr 26

BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shares Lagging The Industry But So Is The Business

Apr 21

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 42% Below Their Intrinsic Value Estimate

May 09

Why Investors Shouldn't Be Surprised By BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Low P/S

Apr 18

These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely

Mar 27

An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 39% Undervalued

Jan 09

BioMarin redesigns organization, will lay off about 4% of its workforce

Oct 07

BioMarin resubmits biologics license application to FDA for hemophilia A gene therapy

Sep 29

BioMarin touts report on cost effectiveness of gene therapy Roctavian for hemophilia A

Sep 15

BioMarin to resubmit hemophilia therapy for FDA approval after EU nod

Aug 25

BioMarin may be an activist target after 13-F filings

Aug 15

BioMarin (BMRN) boosts 2022 top and bottom line guidance on back of product sales growth

Aug 03

BioMarin: More Growth

Jul 21

BioMarin's Solid Pipeline Bears The First Fruit

Jun 27

Would BioMarin Pharmaceutical (NASDAQ:BMRN) Be Better Off With Less Debt?

May 25

BioMarin: A Good Anchor For Your Biotech Portfolio

May 10

BioMarin: Keep Waiting For The Growth

Mar 03

Earnings and Revenue Growth Forecasts

NasdaqGS:BMRN - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	3,437	678	828	1,062	23
12/31/2025	3,089	504	665	871	27
12/31/2024	2,739	363	587	616	28
3/31/2024	2,472	205	173	280	N/A
12/31/2023	2,419	168	52	159	N/A
9/30/2023	2,311	147	25	139	N/A
6/30/2023	2,235	100	34	161	N/A
3/31/2023	2,173	72	15	147	N/A
12/31/2022	2,096	142	148	176	N/A
9/30/2022	2,008	84	151	180	N/A
6/30/2022	1,912	54	106	119	N/A
3/31/2022	1,880	39	134	146	N/A
12/31/2021	1,846	-64	185	305	N/A
9/30/2021	1,849	16	165	280	N/A
6/30/2021	1,917	837	155	269	N/A
3/31/2021	1,844	795	92	214	N/A
12/31/2020	1,860	854	15	85	N/A
9/30/2020	1,863	852	75	156	N/A
6/30/2020	1,847	122	58	140	N/A
3/31/2020	1,805	114	3	88	N/A
12/31/2019	1,704	-24	-90	48	N/A
9/30/2019	1,603	-43	-59	40	N/A
6/30/2019	1,533	-110	-112	17	N/A
3/31/2019	1,519	-90	-87	8	N/A
12/31/2018	1,491	-77	-74	20	N/A
9/30/2018	1,496	-125	-12	-15	N/A
6/30/2018	1,439	-125	-14	-23	N/A
3/31/2018	1,383	-145	-6	29	N/A
12/31/2017	1,314	-117	N/A	-9	N/A
9/30/2017	1,255	-156	N/A	-24	N/A
6/30/2017	1,201	-181	N/A	-72	N/A
3/31/2017	1,184	-563	N/A	-137	N/A
12/31/2016	1,117	-630	N/A	-228	N/A
9/30/2016	1,045	-471	N/A	-293	N/A
6/30/2016	974	-524	N/A	-286	N/A
3/31/2016	924	-187	N/A	-253	N/A
12/31/2015	890	-172	N/A	-219	N/A
9/30/2015	892	-310	N/A	-179	N/A
6/30/2015	859	-212	N/A	-185	N/A
3/31/2015	801	-163	N/A	-183	N/A
12/31/2014	749	-134	N/A	-70	N/A
9/30/2014	666	-126	N/A	-58	N/A
6/30/2014	627	-187	N/A	-59	N/A
3/31/2014	572	-175	N/A	-54	N/A
12/31/2013	548	-176	N/A	-57	N/A
9/30/2013	534	-167	N/A	-36	N/A
6/30/2013	525	-120	N/A	-13	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BMRN's forecast earnings growth (29.8% per year) is above the savings rate (2.4%).

Earnings vs Market: BMRN's earnings (29.8% per year) are forecast to grow faster than the US market (14.7% per year).

High Growth Earnings: BMRN's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: BMRN's revenue (10.8% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: BMRN's revenue (10.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: BMRN's Return on Equity is forecast to be low in 3 years time (12.7%).

BioMarin Pharmaceutical Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Consensus EPS estimates increase by 17%

BioMarin Pharmaceutical Inc. Provides Earnings Guidance for the Year 2024

BioMarin Pharmaceutical Inc. Revises Financial Guidance for the Full Year 2023

Biomarin Pharmaceutical Inc. Updates Earnings Guidance for the Year Ended December 31, 2023

Consensus EPS estimates fall by 13%

Recent updates

BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain

Director notifies of intention to sell stock

Biomarin Pharmaceutical Inc. Announces Positive New Data Supporting the Safety and Efficacy of VOXZOGO® (Vosoritide) in Children

Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

First quarter 2024 earnings: EPS exceeds analyst expectations

Consensus EPS estimates increase by 17%

BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shares Lagging The Industry But So Is The Business

Director notifies of intention to sell stock

BioMarin Pharmaceutical Inc., Annual General Meeting, May 21, 2024

Executive VP notifies of intention to sell stock

Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?

Insider recently sold US$3.0m worth of stock

Insider notifies of intention to sell stock

Biomarin Announces Board Changes, Effective May 20, 2024

BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth

Full year 2023 earnings released: EPS: US$0.89 (vs US$0.76 in FY 2022)

BioMarin Pharmaceutical Inc. Provides Earnings Guidance for the Year 2024

Director notifies of intention to sell stock

BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest?

Biomarin Pharmaceutical Inc. Announces Resignation of Jeffrey Ajer as Executive Vice President and Chief Commercial Officer, Effective from July 1, 2024

Director notifies of intention to sell stock

Little Excitement Around BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Revenues

Director notifies of intention to sell stock

BioMarin Pharmaceutical Inc. Announces Board Appointments, Effective December 27, 2023

Executive VP notifies of intention to sell stock

Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 49% Discount?

Biomarin Pharmaceutical Inc. Announces CEO Changes

Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

BioMarin Pharmaceutical Inc. Revises Financial Guidance for the Full Year 2023

U.S. Food and Drug Administration Approves Biomarin's Voxzogo® (Vosoritide) for Children Under 5 Years with Achondroplasia

Biomarin Pharmaceutical Inc. to Present Data Showing Long-Term Benefit of Vosoritide on Growth in Children with Achondroplasia At 2023 European Society for Paediatric Endocrinology Meeting

BioMarin Pharmaceutical Inc. Announces First Person Treated with ROCTAVIAN (Valoctocogene Rxaparvovec-Rvox) for Severe Hemophilia A in Europe

Executive VP recently sold US$984k worth of stock

Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 42% Discount?

Second quarter 2023 earnings: EPS exceeds analyst expectations

Biomarin Pharmaceutical Inc. Updates Earnings Guidance for the Year Ended December 31, 2023

We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt

Bernstein Litowitz Berger & Grossmann LLP Announces Pendency of Class Action and Proposed Settlement for Purchasers of Biomarin Pharmaceutical Inc

U.S. Food and Drug Administration Approves Biomarin's Roctavian® (Valoctocogene Rxaparvovec-Rvox) Gene Therapy for Adults with Severe Hemophilia A

BioMarin Pharmaceutical Inc. to Present Roctavian™ Data from Longest and Largest Hemophilia Gene Therapy Clinical Trial Program

Chairman & CEO notifies of intention to sell stock

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 42% Below Their Intrinsic Value Estimate

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 13%

Why Investors Shouldn't Be Surprised By BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Low P/S

Independent Director notifies of intention to sell stock

These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely

Chairman & CEO notifies of intention to sell stock

Executive VP & Chief Legal Officer exercised options to buy US$148k worth of stock.

Full year 2022 earnings: EPS exceeds analyst expectations

Consensus EPS estimates fall by 32%

Chairman & CEO notifies of intention to sell stock

BioMarin Pharmaceutical Inc. to Report Q4, 2022 Results on Feb 27, 2023

Executive VP & Chief Commercial Officer notifies of intention to sell stock

Executive VP of Finance & CFO exercised options and sold US$129k worth of stock

Biomarin Pharmaceutical Inc. Announces Stable and Durable Annualized Bleed Control for Roctavian(Tm) in Large Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints At 3-Year Analysis

An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 39% Undervalued

BioMarin Pharmaceutical Inc. Announces That the European Medicines Agency Validated Its Type II Variation Application to Extend the Indication for VOXZOGO® (Vosoritide) for Injection to Treat Children with Achondroplasia Under the Age of 2

BioMarin Pharmaceutical Inc. Announces Advancements in FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) for Adults with Severe Hemophilia A

BioMarin Pharmaceutical Inc. Announces Incremental Progress on Biologics License Application (BLA) Review for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A Program

BioMarin Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2022

FDA Accepts Biomarin's Biologics License Application (Bla) for Valoctocogene Roxaparvovec Aav Gene Therapy for Adults with Severe Hemophilia A

BioMarin redesigns organization, will lay off about 4% of its workforce

BioMarin Pharmaceutical Inc. to Report Q3, 2022 Results on Oct 26, 2022

BioMarin resubmits biologics license application to FDA for hemophilia A gene therapy

BioMarin touts report on cost effectiveness of gene therapy Roctavian for hemophilia A

BioMarin Pharmaceutical Inc. Announces First Gene Therapy for Adults with Severe Hemophilia A, BioMarin's ROCTAVIAN(TM) (valoctocogene roxaparvovec), Approved by European Commission (EC)

BioMarin to resubmit hemophilia therapy for FDA approval after EU nod